Analysts’ Recent Ratings Updates for Spyre Therapeutics (SYRE)

Several analysts have recently updated their ratings and price targets for Spyre Therapeutics (NASDAQ: SYRE):

• 6/23/2026 – Spyre Therapeutics had its price target raised by Deutsche Bank Aktiengesellschaft from $115.00 to $135.00. They now have a “buy” rating on the stock.
• 6/16/2026 – Spyre Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $100.00 price target on the stock.
• 6/15/2026 – Spyre Therapeutics had its price target raised by BTIG Research from $98.00 to $112.00. They now have a “buy” rating on the stock.
• 6/4/2026 – Spyre Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/4/2026 – Spyre Therapeutics had its price target raised by Deutsche Bank Aktiengesellschaft from $102.00 to $115.00. They now have a “buy” rating on the stock.
• 5/12/2026 – Spyre Therapeutics had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $102.00 price target on the stock.
• 5/6/2026 – Spyre Therapeutics had its price target raised by Stifel Nicolaus from $92.00 to $107.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Spyre Therapeutics had its price target raised by Citigroup Inc. from $64.00 to $97.00. They now have a “buy” rating on the stock.
• 4/26/2026 – Spyre Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.

Insider Buying and Selling

In related news, insider Sheldon Sloan sold 8,333 shares of the business’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $75.00, for a total value of $624,975.00. Following the completion of the transaction, the insider directly owned 8,333 shares in the company, valued at $624,975. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott L. Burrows sold 7,500 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $71.06, for a total transaction of $532,950.00. Following the sale, the chief financial officer directly owned 97,994 shares in the company, valued at $6,963,453.64. This trade represents a 7.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 247,124 shares of company stock worth $17,237,760. 15.69% of the stock is currently owned by company insiders.

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.